Nautilus Biotechnology, Inc.NAUTNASDAQ
LOADING
|||
R&D Expense Growth Recovery in Progress
Trending higher, below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-7.63%
↓ 3757% below average
Average (27q)
-0.20%
Historical baseline
Range
High:31.04%
Low:-100.00%
Volatility
-66248.4%
Relatively stable
| Period | Value |
|---|---|
| Q3 2025 | -7.63% |
| Q2 2025 | -10.24% |
| Q1 2025 | 2.06% |
| Q4 2024 | -7.86% |
| Q3 2024 | -1.27% |
| Q2 2024 | -3.95% |
| Q1 2024 | 4.22% |
| Q4 2023 | 3.61% |
| Q3 2023 | -0.14% |
| Q2 2023 | 9.72% |
| Q1 2023 | 13.54% |
| Q4 2022 | -3.45% |
| Q3 2022 | 11.62% |
| Q2 2022 | -8.55% |
| Q1 2022 | -2.63% |
| Q4 2021 | 20.87% |
| Q3 2021 | 31.04% |
| Q2 2021 | 0.00% |
| Q1 2021 | -100.00% |
| Q4 2020 | 11.55% |
| Q3 2020 | 20.57% |
| Q2 2020 | 11.38% |
| Q1 2020 | 0.00% |
| Q4 2019 | 0.00% |
| Q3 2019 | 0.00% |
| Q2 2019 | 0.00% |
| Q1 2019 | 0.00% |
| Q4 2018 | 0.00% |